Study guide

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow

BCSCP Board Certified Sterile Compounding Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, USP Standards & CSP Categories

1.1 BCSCP Exam Format, Eligibility, Scoring & 2024 Content Outline 1.2 USP <797> Scope, Core Philosophy & Regulatory Framework 1.3 USP <797> Categories 1, 2, and 3 CSP Classification 1.4 Immediate-Use CSPs: The 4-Hour Rule and Its Conditions

2 Chapter 2: Facilities, Engineering Controls & Cleaning

2.1 Cleanroom Architecture & ISO Classifications 2.2 Primary Engineering Controls (PECs) & Laminar Airflow Dynamics 2.3 Segregated Compounding Areas (SCAs) & Containment SCAs (C-SCAs) 2.4 HVAC Engineering Controls, Pressure Differentials & Air Exchange 2.5 Equipment & Materials in Classified Areas Under Dynamic Conditions 2.6 Cleaning, Disinfecting, Sporicidal Agents & Sterile 70% IPA 2.7 Contingency Planning: Power, HVAC, Supply and Staffing Failures

3 Chapter 3: Environmental Monitoring & Facility Certification

3.1 Viable Airborne Microbial Monitoring 3.2 Total Airborne Non-Viable Particle Counting & Cleanroom Certification Standards 3.3 Surface Microbial Sampling: Contact Plates, Swabs, Incubation Protocols & Action Levels 3.4 Environmental Sampling Excursions, Trend Analysis, and Remediation Protocols

4 Chapter 4: Hand Hygiene, Garbing & Aseptic Technique

4.1 Hand Hygiene & Cleansing Protocols 4.2 Step-by-Step Garbing Sequence & Ante-Room Logistics 4.3 Direct Compounding Area (DCA) Aseptic Technique & First Air Integrity

5 Chapter 5: Beyond-Use Dating, Storage & Container Rules

5.1 Category 1 Beyond-Use Dating & Storage Limitations 5.2 Category 2 Beyond-Use Dating: Sterile vs. Nonsterile Starting Components 5.3 Category 3 Beyond-Use Dating: Requirements for Extended Dating (60/90/120 Days) 5.4 Container Types, Puncture Limits & Multi-Dose Container Rules

6 Chapter 6: Sterilization, Release Testing & Hazardous Drug Compounding

6.1 Terminal Sterilization vs. Sterilizing Filtration 6.2 Release Testing: Sterility (USP <71>), Endotoxin (USP <85>) & Particulates (USP <788>) 6.3 Container Closure Integrity Testing (CCIT) & Visual Inspection 6.4 USP <800> Hazardous Drug Compounding & Closed System Drug-Transfer Devices (CSTDs)

7 Chapter 7: Materials, Equipment & Compounding Workflow

7.1 Compounding Equipment & Technology: ACDs, Balances, Pumps & IV Workflow Systems 7.2 Compounding Supplies, Containers & Closures 7.3 Component Receipt, Storage & Material Transfer 7.4 Calibration, Verification, Validation & Maintenance of Equipment 7.5 Compounding Workflow: SOPs, Workflow Software, Production Queues & Labeling 7.6 Handling, Storing, Packaging, Transporting & Disposing of Finished CSPs

8 Chapter 8: Calculations, Osmolarity & Physicochemical Compatibility

8.1 Sterile Compounding Calculations: Millimoles, Milliequivalents, Osmolarity & Tonicity Adjustments 8.2 Physical and Chemical Incompatibilities: pH Effects, Salt Formations & Precipitation Mechanisms 8.3 Complex Admixture Compatibility: Calcium-Phosphate Solubility Curves & Parenteral Nutrition Dynamics

9 Chapter 9: Therapeutics, Administration & Patient Monitoring

9.1 Patient-Specific Parameters: Verifying CSP Orders 9.2 Special Administration Routes: Epidural, Intrathecal, Ophthalmic & Intravesical Sterile Preparations 9.3 Medication Delivery Devices, Home Infusion & Patient Education 9.4 High-Alert Sterile Medications, Pediatric/Neonatal Considerations & Extravasation Management 9.5 Therapeutic Drug Monitoring, Catheter-Related Bloodstream Infection (CRBSI) Prevention & Clinical Vigilance 9.6 Medication Adherence in Home and Outpatient Sterile Therapy 9.7 Interprofessional Care Coordination for Sterile Preparations

10 Chapter 10: Quality Management, Records & Personnel Competency

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow 10.2 Personnel Training, Core Competency & Written Testing Requirements 10.3 Gloved Fingertip and Thumb Sampling (GFT) Testing Cadence, Pass/Fail Thresholds & Action Plans 10.4 Media-Fill Testing Protocols: Simulation Design, Incubation Parameters & Failure Investigations 10.5 Standard Operating Procedures & Document Control 10.6 Quality Assurance & Quality Control Programs 10.7 Inspection Methods, Self-Audits & Continuous Readiness 10.8 Literature Evaluation: Research Methods, Statistics & Stability Evidence

11 Chapter 11: Regulatory Oversight, Accreditation & Drug Supply Chain

11.1 Drug Quality and Security Act (DQSA) & FDA Section 503A Traditional Pharmacies vs. Section 503B Outsourcing Facilities 11.2 State Boards of Pharmacy, FDA Guidance & Inter-Agency Regulatory Jurisdictions 11.3 Drug Supply Chain Security Act (DSCSA), Component Qualification & Certificate of Analysis (CoA) Verification 11.4 CMS, The Joint Commission, CDC, ASPEN & ASHP: Standards Beyond USP and FDA

12 Chapter 12: Safety Management, Investigations, Recalls & Waste

12.1 Root Cause Analysis (RCA), CAPA Framework & Out-of-Specification (OOS) Investigations 12.2 Adverse Drug Event Reporting, FDA MedWatch Form 3500 & Product Recall Protocols 12.3 Occupational Safety, Hazardous Waste Disposal (RCRA / EPA) & Spill Clean-up Management

10.1 Master Formulation Records (MFR) vs. Compounding Records (CR) Requirements & Workflow

Key Takeaways Explain This Topic AI

Under USP <797>, a Master Formulation Record (MFR) is required for any CSP made from one or more nonsterile ingredients, or made for more than one patient.

A Compounding Record (CR) is required for every Category 1, 2 and 3 CSP, and for immediate-use CSPs made for more than one patient.

A single-patient CSP made only from sterile components needs a CR but not an MFR. Preparing a conventionally manufactured product exactly per its approved labeling for one patient is not compounding.

The minimum MFR contents (USP <797> Box 9) are: name, strength and dosage form; ingredient identities and amounts; container-closure type and size; complete instructions; physical description; BUD and storage; the stability reference; QC procedures; and other details needed for reproducibility.

The CR (Box 10) records the date and time, an internal ID, the people involved and verifying, each component's amount and strength, lot and expiration data (required for batched or nonsterile-ingredient CSPs), total quantity and yield, BUD and storage, and QC results.

Last updated: September 2026

Regulatory Philosophy: Master Recipe vs. Production Execution

In sterile compounding quality management, documentation provides the legal, clinical, and operational bridge ensuring that every compounded sterile preparation (CSP) reliably meets its identity, purity, potency, and sterility specifications. Under USP General Chapter <797> (2023 Revision) , sterile compounding documentation is built upon a strict two-tiered structural hierarchy:

The Master Formulation Record (MFR) : The permanent, validated "master recipe" and procedural protocol detailing how a specific CSP must be compounded.

The Compounding Record (CR) : The individualized, lot-specific batch execution logbook documenting what actually occurred during a specific compounding event.

Historical root-cause investigations into catastrophic compounding tragedies (most notably the 2012 New England Compounding Center meningitis outbreak) revealed that improper documentation, unvalidated recipe alterations, and absent component traceability were central contributing factors. Consequently, current USP standards enforce rigorous boundaries governing when an MFR is mandated and what data elements must be captured on the CR.

When is a Master Formulation Record (MFR) Mandated?

Under USP <797>, an MFR is not required for every single compound, but it is strictly required under two primary conditions:

Batching for Multiple Patients : Whenever a CSP is prepared for more than one patient in a single compounding session.

Nonsterile Starting Components : Whenever a CSP is compounded from one or more nonsterile raw ingredients, bulk active pharmaceutical ingredients (APIs), or nonsterile components—even if the preparation is prepared for an individual, single patient !

Important

If a sterile preparation is prepared for a single, specific patient from commercially manufactured sterile starting components in strict adherence to manufacturer package insert instructions, an MFR is not mandated. However, a batch-specific Compounding Record (CR) or equivalent documented preparation record must still be completed and maintained.

Mandated Components of the Master Formulation Record (MFR)

An MFR serves as the overarching standard operating procedure for a formulation. It is written and approved before any batch is made, and any change must be approved and documented under the facility's SOPs. USP <797> Box 9 lists the minimum contents:

Name, strength or activity, and dosage form of the CSP (e.g., Morphine Sulfate 50 mg/mL Preservative-Free Epidural Injection ).

Identities and amounts of all ingredients , plus relevant characteristics of components such as particle size, salt form, purity grade and solubility.

Type and size of the container-closure system(s) (e.g., 100 mL EVA bag or Type I glass vial with 20 mm chlorobutyl stopper ).

Complete instructions for preparing the CSP : equipment, supplies, a description of the compounding steps, and any special precautions.

Physical description of the final CSP (appearance, color, clarity).

BUD and storage requirements .

Reference source to support the stability of the CSP.

Quality control (QC) procedures , such as pH testing and filter integrity testing.

Other information needed to describe the process and ensure repeatability , such as pH or tonicity adjustment and the sterilization method (steam, dry heat, irradiation or filtration).

Many facilities also put the required PEC and SEC, labeling templates and acceptance limits into the MFR. That is good practice, but these are not separate Box 9 items. Keep the two apart on the exam: USP's list is the minimum.

The Compounding Record (CR): Real-Time Batch Documentation

While the MFR describes how the product must be made, the Compounding Record (CR) documents the actual execution of a specific compounding event. A unique CR must be created for every single compounded batch or individual preparation. It functions as the permanent legal and clinical audit trail verifying that personnel adhered strictly to the MFR.

Mandated Components of the Compounding Record (CR)

USP <797> Box 10 sets the minimum CR contents: name, strength and dosage form; date and time of preparation; an internal identification number; a way to identify the people who compounded and verified the CSP; each component's name, weight or volume and strength; vendor, lot number and expiration date for each component when the CSP is for more than one patient or has nonsterile ingredients; total quantity compounded; final yield; BUD and storage; and QC results. If applicable, it also includes the MFR reference and the calculations. A typical batch CR expands on this:

MFR Reference : The exact name, unique identification code, and revision version number of the MFR utilized.

Internal Lot or Tracking Number : A unique, internally generated identification number assigned to that specific batch (e.g., LOT-20260929-004 ).

Component Traceability : For every raw chemical, API, commercial drug vial, diluent, filter, and container-closure used:

  • Exact component name
  • Manufacturer / supplier / vendor name
  • Manufacturer commercial lot number
  • Manufacturer expiration date
  • Certificate of Analysis (CoA) reference (for nonsterile bulk substances)

Actual Measured Quantities : Exact raw tare weights, gross weights, net component weights, and liquid volumes measured during preparation (often evidenced by attached analytical balance printouts).

Calculations and Verifications : The calculations used to determine and verify quantities and concentrations (required if applicable). Independent double checks are facility practice.

Personnel Identification : USP requires a method to identify the people involved and those who verify the final CSP. Facilities typically record names or electronic credentials of:

  • The individual(s) who physically prepared the CSP (technician or pharmacist)
  • The pharmacist who performed in-process component checks
  • The supervising pharmacist who verified and released the finished batch

Date and Time : The date and time of preparation.

Assigned BUD and Storage : The calculated beyond-use date and storage specifications matching the MFR.

Quality Control Results : Empirical records of all release checks performed on that batch:

  • Visual inspection results (clarity, container integrity, lack of particulates)
  • Measured pH value
  • Actual batch volume or unit count yield

Post-filtration filter integrity test results (e.g., measured bubble point: 48 psi; passes manufacturer minimum specification of 45 psi )

Analytical assay, sterility, or endotoxin results (if applicable)

Total Quantity Prepared : The actual number of units compounded (e.g., 100 minibags compounded: 98 units placed into inventory, 2 units sacrificed for destruct quality control testing ).

Label Reconciliation (practice): Checking that the number of printed labels matches the units prepared, and destroying unused labels, prevents mislabeling.

Comparative Matrix: MFR vs. CR

Parameter Master Formulation Record (MFR) Compounding Record (CR)

Primary Purpose Master recipe, standard operating procedure, and release standard Real-time batch production log and clinical/legal audit trail

Creation Timing Authored and approved prior to compounding any batch Generated and filled out during the active compounding session

USP <797> Mandate Required for all multi-patient batches or any preparation from nonsterile starting components Required for every single compounded sterile preparation or batch

Component Details Generic names, purity grades, and theoretical amounts Specific manufacturers, commercial lot numbers, expiration dates, and actual measured weights

Quality Testing Predetermined acceptance criteria and test methodologies Empirical test results obtained from that specific batch (e.g., measured bubble point psi)

Personnel Data Authored and approved by designated compounding pharmacist Signatures of compounding technician, in-process checker, and release pharmacist

Reconciliation Theoretical yield specifications Actual yield, units sacrificed for testing, and label reconciliation count

Audit Trails, Discrepancies & Regulatory Archival

USP <797> requires records to be legible, protected from loss, readily retrievable, and compliant with the record-keeping laws of the jurisdiction. The state board's retention period is what inspectors enforce for 503A pharmacies; for comparison, USP <795> keeps nonsterile compounding records for at least 3 years after preparation. Outsourcing facilities follow CGMP, which requires batch records to be kept at least 1 year after the batch's expiration date (21 CFR 211.180). Records may be archived in paper format or in electronic systems that comply with immutable audit trail standards (e.g., role-based access, date/time stamping, and electronic signature integrity).

Handling Discrepancies and Out-of-Specification (OOS) Results

If any parameter recorded on the CR fails to meet the acceptance criteria established in the MFR (e.g., the measured pH is outside the target window, a filter bubble point pressure falls below the validated threshold, or the yield falls outside the tolerance set in the MFR), the batch cannot be released as it is.

Caution

Compounding personnel must never alter MFR acceptance criteria retroactively to fit a substandard batch. Any deviation must trigger an immediate Out-of-Specification (OOS) investigation , root-cause analysis, batch quarantine, and formal supervisory review.